Cargando…

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey

BACKGROUND: The introduction of carbidopa-levodopa extended-release (CD-LD ER) capsules (Rytary®) did not go as smoothly as expected, largely due to difficulty around dose conversion from available immediate-release (IR) levodopa (LD) formulations. The dose conversion table in the CD-LD ER prescribi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Banisadr, Ghazal, Vuong, Kara, Freilich, David, Fisher, Stanley, D'Souza, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914099/
https://www.ncbi.nlm.nih.gov/pubmed/33688424
http://dx.doi.org/10.1155/2021/6638088
_version_ 1783656956798435328
author Hauser, Robert A.
Banisadr, Ghazal
Vuong, Kara
Freilich, David
Fisher, Stanley
D'Souza, Richard
author_facet Hauser, Robert A.
Banisadr, Ghazal
Vuong, Kara
Freilich, David
Fisher, Stanley
D'Souza, Richard
author_sort Hauser, Robert A.
collection PubMed
description BACKGROUND: The introduction of carbidopa-levodopa extended-release (CD-LD ER) capsules (Rytary®) did not go as smoothly as expected, largely due to difficulty around dose conversion from available immediate-release (IR) levodopa (LD) formulations. The dose conversion table in the CD-LD ER prescribing information was similar to the table used in the pivotal clinical trial and is considered by many prescribing HCPs to be less than optimal. By the end of the dose conversion period in that trial, dosing in 76% of subjects was adjusted for symptom control; roughly 60% of patients required a higher dose and about half required more frequent administration than the recommended TID dosing. OBJECTIVE: The primary objective of our nationwide (US) survey was to determine the dose conversion strategy most commonly employed by CD-LD ER frequent prescribers. The survey also aimed to explore additional features regarding CD-LD ER use in clinical practice. METHODS: A survey consisting of 21 multiple-choice questions was developed and administered to experts in the use of CD-LD ER, based on prescription volume. RESULTS: Of the 394 HCPs who were invited to participate, 90 (23%) HCPs completed the survey. All respondents were aware of the dose conversion table; the largest group did not find the table to be helpful and did not use it to convert patients to CD-LD ER. The most common strategy in calculating the CD-LD ER dose was based on the total daily LD IR dose, with the majority of that group initiating dose conversion by doubling the total daily LD dose from CD-LD IR and administering CD-LD ER one less time per day. CONCLUSION: Overall, most survey respondents agreed that a good starting point for CD-LD ER conversion could be doubling the daily LD IR dose and administering it one time less frequently. Moreover, rapid patient follow-up after initial dose conversion to allow for further dose adjustments plays a critical role in achieving success. Gaining experience over time is important for satisfactory conversion.
format Online
Article
Text
id pubmed-7914099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-79140992021-03-08 Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey Hauser, Robert A. Banisadr, Ghazal Vuong, Kara Freilich, David Fisher, Stanley D'Souza, Richard Parkinsons Dis Research Article BACKGROUND: The introduction of carbidopa-levodopa extended-release (CD-LD ER) capsules (Rytary®) did not go as smoothly as expected, largely due to difficulty around dose conversion from available immediate-release (IR) levodopa (LD) formulations. The dose conversion table in the CD-LD ER prescribing information was similar to the table used in the pivotal clinical trial and is considered by many prescribing HCPs to be less than optimal. By the end of the dose conversion period in that trial, dosing in 76% of subjects was adjusted for symptom control; roughly 60% of patients required a higher dose and about half required more frequent administration than the recommended TID dosing. OBJECTIVE: The primary objective of our nationwide (US) survey was to determine the dose conversion strategy most commonly employed by CD-LD ER frequent prescribers. The survey also aimed to explore additional features regarding CD-LD ER use in clinical practice. METHODS: A survey consisting of 21 multiple-choice questions was developed and administered to experts in the use of CD-LD ER, based on prescription volume. RESULTS: Of the 394 HCPs who were invited to participate, 90 (23%) HCPs completed the survey. All respondents were aware of the dose conversion table; the largest group did not find the table to be helpful and did not use it to convert patients to CD-LD ER. The most common strategy in calculating the CD-LD ER dose was based on the total daily LD IR dose, with the majority of that group initiating dose conversion by doubling the total daily LD dose from CD-LD IR and administering CD-LD ER one less time per day. CONCLUSION: Overall, most survey respondents agreed that a good starting point for CD-LD ER conversion could be doubling the daily LD IR dose and administering it one time less frequently. Moreover, rapid patient follow-up after initial dose conversion to allow for further dose adjustments plays a critical role in achieving success. Gaining experience over time is important for satisfactory conversion. Hindawi 2021-02-19 /pmc/articles/PMC7914099/ /pubmed/33688424 http://dx.doi.org/10.1155/2021/6638088 Text en Copyright © 2021 Robert A. Hauser et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hauser, Robert A.
Banisadr, Ghazal
Vuong, Kara
Freilich, David
Fisher, Stanley
D'Souza, Richard
Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
title Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
title_full Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
title_fullStr Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
title_full_unstemmed Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
title_short Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
title_sort real-world experience with carbidopa-levodopa extended-release capsules (rytary(®)): results of a nationwide dose conversion survey
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914099/
https://www.ncbi.nlm.nih.gov/pubmed/33688424
http://dx.doi.org/10.1155/2021/6638088
work_keys_str_mv AT hauserroberta realworldexperiencewithcarbidopalevodopaextendedreleasecapsulesrytaryresultsofanationwidedoseconversionsurvey
AT banisadrghazal realworldexperiencewithcarbidopalevodopaextendedreleasecapsulesrytaryresultsofanationwidedoseconversionsurvey
AT vuongkara realworldexperiencewithcarbidopalevodopaextendedreleasecapsulesrytaryresultsofanationwidedoseconversionsurvey
AT freilichdavid realworldexperiencewithcarbidopalevodopaextendedreleasecapsulesrytaryresultsofanationwidedoseconversionsurvey
AT fisherstanley realworldexperiencewithcarbidopalevodopaextendedreleasecapsulesrytaryresultsofanationwidedoseconversionsurvey
AT dsouzarichard realworldexperiencewithcarbidopalevodopaextendedreleasecapsulesrytaryresultsofanationwidedoseconversionsurvey